The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
BJU International, 07/27/2012
Clinical Article
Goyal J et al. – Patients that were treated with docetaxel for metastatic castration–resistant prostate cancer showed a significantly longer overall survival when enrolled in a clinical trial. Improved survival in trial participants may reflect the better medical oversight typically seen in patients enrolled in trials, more regimented follow–up schedules, or a positive effect on caregivers' attitudes because of greater contact with medical services.
